{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:33:19Z","timestamp":1787801599635,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Liposomal formulations may improve the solubility and bioavailability of drugs potentially increasing their ability to cross the blood-brain barrier. We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Patients with glioblastoma who progressed after at least 1 line of therapy were eligible. All patients received TMZ 50\u2009mg\/m<jats:sup>2<\/jats:sup>\/d until disease progression. Three dose levels of nal-IRI were planned, 50, 70, and 80\u2009mg\/m<jats:sup>2<\/jats:sup>, intravenously every 2 weeks. Patients were accrued in a 3+3 design. The study included a preliminary assessment after the first 13 evaluable patients. The trial would be terminated early if 0 or 1 responses were observed in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twelve patients were treated over 2 dose levels (nal-IRI 50 and 70\u2009mg\/m<jats:sup>2<\/jats:sup>). At dose level 2, nal-IRI 70\u2009mg\/m<jats:sup>2<\/jats:sup>, 2 of 3 patients developed dose-limiting toxicities including 1 patient who developed grade 4 neutropenia and grade 3 diarrhea and anorexia and 1 patient with grade 3 diarrhea, hypokalemia fatigue, and anorexia. Accrual to dose level 1 was expanded to 9 patients. The Drug Safety Monitoring Board (DSMB) reviewed the data of the initial 12 patients\u2014there were 0\/12 responses (0%) and the median progression-free survival was 2 months and accrual was halted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The maximum tolerated dose of nal-IRI was 50\u2009mg\/m<jats:sup>2<\/jats:sup> every 2 weeks with TMZ 50\u2009mg\/m<jats:sup>2<\/jats:sup>\/d. The dose-limiting toxicities were diarrhea and neutropenia. No activity was seen at interim analysis and the study was terminated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000780","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:18:04Z","timestamp":1607300284000},"page":"49-52","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Heinrich","family":"Elinzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Toms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Robison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arieana","family":"Carcieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deus","family":"Cielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Disano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vatketich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Baekey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlee","family":"Sturtevant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"MacKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Safran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant TMZ for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol"},{"key":"R3-20250527","first-page":"2473","article-title":"Salvage TMZ for prior TMZ responders","volume":"104","author":"Franceschi","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1215\/15228517-2008-078","article-title":"New (alternative) TMZ regimens for the treatment of glioma","volume":"11","author":"Wick","year":"2008","journal-title":"Neuro-Oncology"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3892\/etm.2011.207","article-title":"Metronomic treatment of TMZ increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells","volume":"2","author":"Ko","year":"2011","journal-title":"Exp Ther Med"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3340\/jkns.2015.58.5.426","article-title":"Continuous low-dose TMZ chemotherapy and microvessel density in recurrent glioblastoma","volume":"58","author":"Woo","year":"2015","journal-title":"J Korean Neurosurg Soc"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/annonc\/mdp591","article-title":"Bevacizumab and dose-intense TMZ in recurrent high-grade glioma","volume":"21","author":"Verhoeff","year":"2010","journal-title":"Ann Oncol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nnano.2015.311","article-title":"A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways","volume":"11","author":"Spring","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.2217\/nnm.13.201","article-title":"Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors","volume":"9","author":"Noble","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1200\/JCO.2006.06.7272","article-title":"Irinotecan plus TMZ for relapsed or refractory neuroblastoma","volume":"24","author":"Kushner","year":"2006","journal-title":"J Clin Oncol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and TMZ for Ewing sarcoma: The Memorial Sloan-Kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5430\/jst.v5n2p105","article-title":"Irinotecan and TMZ in adults with recurrent sarcoma","volume":"5","author":"Blanchette","year":"2015","journal-title":"J Solid Tumors"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14737140.2016.1174581","article-title":"Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer","volume":"16","author":"Rehman","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.2018.36.4_suppl.388","article-title":"Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil\/leucovorin (5-FU\/LV) in NAPOLI-1: impact on efficacy","volume":"36","author":"Wang-Gillam","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:10Z","timestamp":1748365690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000780"}},"subtitle":["BrUOG329, A Phase I Brown University Oncology Research Group Trial"],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000780","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}